Home › Funds › Soleus Capital Management, L.P. › AVLN
Soleus Capital Management, L.P. position in AVLN
AVALYN PHARMACEUTICALS INC · Health Care
Soleus Capital Management, L.P. reported holding 1,019,000 shares of AVLN (AVALYN PHARMACEUTICALS INC) in its Q3 2026 13F filing — a position valued at US$29.0M, representing 1.03% of its reported portfolio and ranking #24 among its reported holdings. Soleus Capital Management, L.P. has disclosed AVLN holdings in 2 of the last 2 reported quarters, going back to Q2 2026.
Last updated: 2026-11-17 · Source: SEC EDGAR Form 13F-HR
How Soleus Capital Management, L.P.'s AVLN position evolved
Soleus Capital Management, L.P. first disclosed a stake in AVLN in Q2 2026 at 419,000 shares (US$13.8M). The position peaked in Q3 2026 at 1,019,000 shares, worth US$29.0M. Across 2 filings, Soleus Capital Management, L.P. increased the stake 1 time(s), trimmed it 0 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 1,019,000 shares valued at US$29.0M — an increase of 600,000 shares quarter over quarter.. Notable position changes include a 143% increase in Q3 2026 (shares rose 4% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q2 2026 | 419.00K | $13.79M | New |
| Q3 2026 | 1.02M | $29.03M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About AVLN and 13F data
AVLN (AVALYN PHARMACEUTICALS INC) is a Health Care company. 114 other funds we track also report a position in AVLN — the largest reported positions include Novo Holdings A/S (US$98.3M), SR ONE CAPITAL MANAGEMENT, LP (US$94.3M), PERCEPTIVE ADVISORS LLC (US$76.2M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding AVLN
- Novo Holdings A/S 3.45M sh · $98.27M · Q3 2026
- SR ONE CAPITAL MANAGEMENT, LP 3.31M sh · $94.26M · Q3 2026
- PERCEPTIVE ADVISORS LLC 2.68M sh · $76.22M · Q3 2026
- MONTANOVA CAPITAL, LLC 2.50M sh · $71.31M · Q3 2026
- NVP Associates, LLC 2.27M sh · $64.63M · Q3 2026
- Catalio Capital Management, LP 1.70M sh · $48.40M · Q3 2026
- Bellevue Group AG 1.35M sh · $38.46M · Q3 2026
- Andera Partners 929.82K sh · $26.49M · Q3 2026
- Pivotal bioVenture Partners Investment Advisor LLC 866.79K sh · $24.69M · Q3 2026
- TPG GP A, LLC 773.07K sh · $22.02M · Q3 2026
- BRAIDWELL LP 744.46K sh · $21.21M · Q3 2026
- DEERFIELD MANAGEMENT COMPANY, L.P. 731.00K sh · $20.83M · Q3 2026
More on Soleus Capital Management, L.P.
FAQ
How long has Soleus Capital Management, L.P. held AVLN?
Soleus Capital Management, L.P. has disclosed AVLN holdings in 2 of the last 2 reported quarters, going back to Q2 2026.
What is Soleus Capital Management, L.P.'s current position in AVLN?
As of Q3 2026, Soleus Capital Management, L.P. holds 1.02M shares of AVLN (AVALYN PHARMACEUTICALS INC), valued at $29.03M, representing 1.03% of its reported portfolio and ranking #24.
Has Soleus Capital Management, L.P. been buying or selling AVLN?
In the latest 13F filing (Q3 2026), Soleus Capital Management, L.P. increased its position in AVLN. The position peaked in Q3 2026 at 1.02M shares.
Which other funds hold AVLN?
Other major institutional holders of AVLN include Novo Holdings A/S, SR ONE CAPITAL MANAGEMENT, LP, PERCEPTIVE ADVISORS LLC, among 114 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.